WuXi Biologics (Cayman)WXIBF +17.00%97 PS Ratio is 6.38 as of Jul. 05, 2026, which is 78% below its 10-year median of 28.58. GuruFocus rates WXIBF with a GF Score™ of 97/100 and a GF Value™ of $4.77 (Fairly Valued). The stock has 3 warning signs investors should review. Among 931 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 60.47% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, WuXi Biologics (Cayman)'s share price is $4.68.
WuXi Biologics (Cayman)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.73. Hence, WuXi Biologics (Cayman)'s PS Ratio for today is 6.38.
The historical rank and industry rank for WuXi Biologics (Cayman)'s PS Ratio or its related term are showing as below:
WXIBF'
s PS Ratio Range Over the Past 10 Years
Min: 2.39 Med: 28.58 Max: 90.01
Current: 6.55
During the past 12 years, WuXi Biologics (Cayman)'s highest PS Ratio was 90.01. The lowest was 2.39. And the median was 28.58.
WXIBF's PS Ratio is ranked better than 60.47% of 931
companies
in the Biotechnology industry
Industry Median: 9.93
vs WXIBF: 6.55
WuXi Biologics (Cayman) Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of WuXi Biologics (Cayman) was 22.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 26.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 41.30% per year.
During the past 12 years, WuXi Biologics (Cayman)'s highest 3-Year average Revenue per Share Growth Rate was 65.30% per year. The lowest was 13.90% per year. And the median was 50.40% per year.
Back to Basics: PS Ratio
WuXi Biologics (Cayman) (OTCPK:WXIBF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PS Ratio distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
WuXi Biologics (Cayman)'s Share Price of today is $4.68.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. WuXi Biologics (Cayman)'s Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
WuXi Biologics (Cayman) (WXIBF) has a PS Ratio of 6.38 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on WuXi Biologics (Cayman) and its competitors. This is 78% below median its historical median of 28.58. Over the past decade, WuXi Biologics (Cayman)'s PS Ratio has ranged from 2.39 to 90.01. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #368 out of 931 companies in the Biotechnology industry, placing it in the top 39.5%.
Is WuXi Biologics (Cayman)'s PS Ratio too high?
WuXi Biologics (Cayman)'s current PS Ratio of 6.38 is 78% below median its 10-year median of 28.58. Over the past 10 years, this metric has ranged from a low of 2.39 to a high of 90.01. The Biotechnology industry median PS Ratio is 9.93. WuXi Biologics (Cayman)'s value of 6.38 is 35.8% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #368 out of 931 companies in the Biotechnology industry, which is above the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #368 out of 931 companies for PS Ratio. This puts WuXi Biologics (Cayman) in the upper half of its industry. The industry median PS Ratio is 9.93. WuXi Biologics (Cayman)'s value of 6.38 is 35.8% below this benchmark. Historically, WuXi Biologics (Cayman)'s own PS Ratio has ranged from 2.39 to 90.01 over the past decade. While the company's 10-year median is 28.58 vs. the industry median of 9.93, WuXi Biologics (Cayman) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.93, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current PS Ratio of 6.38 is 35.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median PS Ratio is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current PS Ratio is 6.38, which is 78% below median its own 10-year median of 28.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Fairly Valued. The stock's GF Value™ is $4.77, compared to a current price of $4.68 — trading 1.9% below its estimated fair value. The current PS Ratio is 6.38, which is 78% below median its 10-year median of 28.58 and 35.8% below the Biotechnology industry median of 9.93. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current PS Ratio is 6.38 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.68 is trading 1.9% below its estimated GF Value™ of $4.77.
GuruFocus considers WuXi Biologics (Cayman) to be Fairly Valued.
Key valuation signals for WXIBF:
PS Ratio: 6.38 (78% below median its 10-year median of 28.58)
GF Value™: $4.77 vs. price of $4.68 (1.9% below fair value)
Industry Position: 35.8% below the Biotechnology median (#368 of 931)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
